NKGen Biotech, Inc.

NKGen Biotech, Inc. is a clinical-stage biotechnology company dedicated to the development and commercialization of innovative natural killer (NK) cell therapies. The company's mission is to enhance immune function and improve patients' lives through its proprietary SNK (super-activated) platform, aiming to become a global leader in immune cell therapeutics. Headquartered in Santa Ana, California, NKGen Biotech focuses on addressing significant unmet medical needs in both neurodegenerative and oncological diseases.

Utilizing its proprietary SNK platform, NKGen Biotech's pipeline includes key product candidates such as SNK01, also known as troculeucel, and SNK02. Troculeucel (SNK01) is an autologous NK cell therapy candidate currently in Phase I/IIa and Phase 2 clinical trials for neurodegenerative conditions like Alzheimer's disease, Parkinson's disease, and Frontotemporal Dementia, as well as various oncological indications including solid tumors. SNK02 is an allogeneic NK cell therapy that has completed Phase 1 trials and includes a HER2-CAR NK cell therapy candidate in preclinical development for refractory solid tumors.

Recent notable developments for NKGen Biotech include the completion of its acquisition of former parent company NKMax Co., Ltd. in September 2025, which granted NKGen full control over global manufacturing operations and intellectual property. The company has presented positive interim Phase 1 data for troculeucel in Alzheimer's disease, demonstrating cognitive improvements and biomarker correlations. Additionally, the U.S. FDA has granted Fast Track designation for troculeucel in moderate Alzheimer's disease and authorized an Expanded Access Program (EAP) for neurodegenerative conditions. Paul Y. Song, MD, serves as the Chairman and Chief Executive Officer, having recently invested personal funds to accelerate the company's Phase 2 Alzheimer's trial. The company transitioned its stock listing from Nasdaq to the OTC Markets (OTC:NKGN) in March 2025, with plans to apply for the OTCQX tier.